An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus

NCT01876849 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

275

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: exenatide

Sponsor

AstraZeneca

Collaborators

[object Object]